<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:regn="http://regeneron.com/20201231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_regn_regeneron.com_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20201231_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="regn-20201231.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-12-31to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-31</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>



<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0"></p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20201231__20201231_zGaol5jGSTjk"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>the Securities Exchange Act of 1934</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Date
of Report (Date of earliest event reported)</b></span>: <span style="font-size: 10pt"><b>January 5, 2021 (<span id="xdx_90D_edei--DocumentPeriodEndDate_c20201231__20201231_zEAaJay5bVx9"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December
31, 2020</ix:nonNumeric></span></b></span><b><span style="font-size: 10pt">)</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20201231__20201231_zGQ9WTlYhuBl"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20201231__20201231_zGxiD8oAHPJh"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New
York</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction of incorporation)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 51%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_906_edei--EntityFileNumber_c20201231__20201231_zQKyWouKC29l"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 48%"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20201231__20201231_zdDheMrJowxe"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt"><b>(Commission<br />
    File Number)</b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="vertical-align: top"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(I.R.S.
                                    Employer</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Identification
        No.)</b></span></p></td></tr>
<tr>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
<tr>
    <td style="text-align: center; vertical-align: top"><span id="xdx_90E_edei--EntityAddressAddressLine1_c20201231__20201231_zrhHSfwnuBn4" style="font-size: 10pt"><b><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityAddressAddressLine1">777
Old Saw Mill River Road,</ix:nonNumeric> </b></span><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20201231__20201231_zSKfJrbGobml" style="font-size: 10pt"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span></b><b><span style="font-size: 10pt">, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20201231__20201231_zqmZnaQsr475"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New
York</ix:nonNumeric></span></span></b><b></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span id="xdx_909_edei--EntityAddressPostalZipCode_c20201231__20201231_zwn0HHcuYfZ5"><b><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></b></span></td></tr>
<tr>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt"><b>(Address of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(Zip Code)</b></td></tr>
</table>

<p style="margin: 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code:</b>  <b>(<span id="xdx_90C_edei--CityAreaCode_c20201231__20201231_zGrFYW0KmCmi"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:CityAreaCode">914</ix:nonNumeric></span></b><b>) <span id="xdx_90A_edei--LocalPhoneNumber_c20201231__20201231_z32TykiM63Eg"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_908_edei--WrittenCommunications_c20201231__20201231_zKgIlYJqW77e" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric>
</span>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_90F_edei--SolicitingMaterial_c20201231__20201231_zRlI7l1bA2Wg" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric>
</span>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_902_edei--PreCommencementTenderOffer_c20201231__20201231_zDCWmxoFc7Ol" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric>
</span>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20201231__20201231_zkZmb4dMI9N3"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> &#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; border-image: none; width: 32%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Title
    of each class</span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; width: 32%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; width: 32%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Name
    of <span style="text-transform: lowercase">Each Exchange on Which R</span>egistered</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20201231__20201231_zYJ51D8gyep7"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20201231__20201231_zHshllqw0NQ"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20201231__20201231_zfjC7Gpf1B44"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20201231__20201231_zoXHa7CZO0Z2"><ix:nonNumeric contextRef="From2020-12-31to2020-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 45pt"><b>Item 5.02</b></td><td><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective December 31, 2020 (the &#8220;<span style="text-decoration: underline">Grant
Date</span>&#8221;), the Compensation Committee (the &#8220;<span style="text-decoration: underline">Compensation Committee</span>&#8221;) of the Board of Directors (the &#8220;<span style="text-decoration: underline">Board</span>&#8221;)
of Regeneron Pharmaceuticals, Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221; or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) granted, and the non-employee
members of the Board approved, in lieu of the next five years of equity awards, a special five-year front-load performance-based
equity award under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the &#8220;<span style="text-decoration: underline">Equity
Plan</span>&#8221;) to each of Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company (&#8220;<span style="text-decoration: underline">CEO</span>&#8221;),
and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company (&#8220;<span style="text-decoration: underline">CSO</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In revising the compensation structure,
the Board took into account shareholder preference for this type of performance-based award. The Board also recognized the Company&#8217;s
long track record of success for patients, shareholders, and employees achieved under the leadership of Drs. Schleifer and Yancopoulos,
as well as the Board&#8217;s confidence in their vision for the Company and stewardship of Regeneron for the foreseeable future.
The awards are 100% performance-based and are designed to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top; text-align: left">
    <td style="font-size: 10pt; width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">further align CEO and CSO interests with those of Regeneron&#8217;s long-term shareholders
    by rewarding top performance and eliminating time-based stock options from their compensation program;</span></td></tr>
<tr style="font-size: 10pt; vertical-align: top; text-align: left">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font-size: 10pt; vertical-align: top; text-align: left">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">reward exceptional shareholder value creation over the next eight years (<i>i.e.</i>, over
    the five-year performance period and the subsequent three-year mandatory deferral and holding period); and</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>ensure stability and continuity of leadership to support the achievement of the next phase of Regeneron&#8217;s ambitious product,
pipeline, and talent development plans.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Historically, annual equity awards to Drs.
Schleifer and Yancopoulos overwhelmingly consisted of time-based stock options. In contrast, the current awards consist entirely
of performance restricted stock units (&#8220;<span style="text-decoration: underline">PSUs</span>&#8221;). The PSUs will be earned based on <span style="color: #231F20">predetermined,
cumulative total shareholder return (&#8220;<span style="text-decoration: underline">TSR</span>&#8221;) goals with respect to the Company&#8217;s common stock </span>over
five years based on <span style="color: #231F20">$478.30 (the most recent closing price of the Company&#8217;s common stock at
the time of grant) (the &#8220;<span style="text-decoration: underline">Initial Share Price</span>&#8221;); </span>the PSUs will vest (to the extent earned) at the end
of the five-year performance period and include a three-year holding requirement once vested, providing for long-term alignment
with shareholders and long-term value creation. PSUs above the threshold level are only earned based on achievement of absolute
TSR performance. At the target level, PSUs will be earned based on an absolute TSR goal of 65.6%; and maximum payout will only
be earned upon achievement of an absolute TSR goal of 140.4%. Each of the awards to Drs. Schleifer and Yancopoulos provides for
a target number of 248,108 PSUs and has an aggregate grant date fair value for accounting purposes of approximately $130 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The awards were designed following detailed
and extensive analysis conducted by the Compensation Committee&#8217;s independent compensation consultant under the Compensation
Committee&#8217;s direction. As a condition to the grant of these awards, it has been agreed that Drs. Schleifer and Yancopoulos
 will not be entitled to any additional equity or equity-based awards from the Company until the Company&#8217;s regular year-end
grant cycle in December 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The terms of the PSUs are further described
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="color: black"><i>Primary Performance
Measure, </i></span><i><span style="color: #231F20">Performance Period, and Payout Range</span></i><span style="color: #231F20">.
The PSUs have a primary performance period of five years from the Grant Date. Between 50% and 250% of the target number of PSUs
granted to the recipient may become eligible to vest upon achievement of absolute TSR goals that were derived from compound five-year
annual growth rates (&#8220;<span style="text-decoration: underline">CAGR</span>&#8221;) of 5.6% (threshold) to 19.2% (maximum), as set forth in the schedule below: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30pt; color: #231F20; text-align: center"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Performance Level</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Absolute
    TSR Goal<sup>1</sup></b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">TSR CAGR</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Price
    Target<sup>2</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Payout<sup>3</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Maximum</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">+140.4%</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">+19.2%</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="width: 17%; font-size: 10pt; font-weight: bold; text-align: right">$ 1,150</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 17%; font-size: 10pt; font-weight: bold; text-align: right">250</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+125.6%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+17.7%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 1,079</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">225</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+112.4%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+16.3%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 1,016</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">200</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+99.9%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+14.9%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 956</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">175</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+87.7%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+13.4%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 898</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">150</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+76.5%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+12.0%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 844</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">125</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Target</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">+65.6%</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">+10.6%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 792</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+47.6%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt">+8.1%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">$ 706</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Threshold</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">+31.3%</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">+5.6%</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: right">$ 628</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">50</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 12.5pt"></td><td style="width: 10pt"><b><sup>1</sup></b></td><td>Starting from the Initial Share Price; <span style="color: #231F20">to be adjusted for any dividends or other shareholder distributions
paid during the performance period. </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 12.5pt"></td><td style="width: 10pt"><b><sup>2</sup></b></td><td><span style="color: #231F20">Determined by applying the five-year TSR CAGR goals to the Initial Share Price; to be adjusted
for any dividends or other shareholder distributions paid out during the performance period.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 12.5pt"></td><td style="width: 10pt"><b><sup>3</sup></b></td><td><span style="color: #231F20">Payouts are expressed as a percentage of the target number of PSUs awarded to each
                                                                               recipient. Payouts for performance between the levels set forth in this table are determined by interpolation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Performance Goal Measurement</i>. The
PSUs may be earned at the threshold level beginning March 15, 2021 and may be earned above the threshold level only after the third
anniversary of the Grant Date, in each case based on the average closing price of the Company&#8217;s common stock over any 20
consecutive trading days. If and to the extent earned, the PSUs vest 100% at the five-year
anniversary of the Grant Date, subject to the recipient&#8217;s continued service at that time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 30pt 0pt 0; color: #231F20; text-indent: 0.5in"><i>Secondary Performance
Measure</i>. If no PSUs have been earned during the five-year performance period, then the recipient will have an opportunity to
earn a threshold payout at 50% of the target number of PSUs if the Company&#8217;s cumulative TSR over such five-year period exceeds,
on a relative basis, the cumulative TSR of the Nasdaq Biotech Index (composite return) by at least 200 basis points. The rationale
for the minimum payout for exceeding the industry five-year index is that there may be circumstances in which Regeneron outperforms
the broader market without reaching the minimum absolute TSR goals, such as in the case of a recession or industry-wide developments
outside management&#8217;s control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Holding Period</i>. Earned PSUs are generally
subject to a mandatory deferral and holding period of three years after vesting (the &#8220;<span style="text-decoration: underline">Holding Period</span>&#8221;). Earned
and vested PSUs are not forfeited upon termination of the recipient&#8217;s service with the Company, but the shares deliverable
in respect of the PSUs may not be sold or otherwise transferred during the Holding Period (except as described below). The Holding
Period ends early upon the recipient&#8217;s death or disability or a change in control involving the Company <span style="color: black">(a
&#8220;<span style="text-decoration: underline">CIC</span>&#8221;)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Termination Treatment</i>. The PSUs will
continue to be outstanding and may be earned and vest for so long as the recipient serves as an employee or consultant of the Company
or a member of the Board. The following provisions further apply to the PSUs in the circumstances described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td><span style="text-decoration: underline">Voluntary Termination or Retirement</span>. Upon voluntary termination or retirement from the Company (except where the recipient&#8217;s
service continues as noted above), any unvested PSUs are forfeited.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td><span style="text-decoration: underline">Termination without Cause/Departure for Good Reason</span>. If the recipient&#8217;s employment with Regeneron is terminated
without Cause or the recipient leaves his employment with Regeneron for a Good Reason (each as defined in or incorporated by reference
into the Equity Plan or the applicable PSU Award Agreement (as defined below)), earnout is measured as of termination and all PSUs
earned as of that date vest and remain subject to the Holding Period. In this circumstance, PSUs not earned as of such termination
date have 12 additional months to be earned and, to the extent earned, will vest on the fifth anniversary of the Grant Date or the first
anniversary of the termination, whichever comes first (with the Holding Period beginning upon such vesting). Unearned PSUs are
forfeited at the end of the 12 months.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td><span style="text-decoration: underline">Change in Control</span>. In the case of a CIC, earnout is measured as of the CIC date (using the CIC transaction price), and
all PSUs earned as of that date vest with no Holding Period and any unearned PSUs are forfeited immediately.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td><span style="text-decoration: underline">Death or Disability</span>. In the case of the recipient&#8217;s death or disability, the PSUs remain outstanding and may be
earned during their term and, to the extent earned, are not subject to the Holding Period.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>PSU Award Agreements</i>. The PSU awards
are made pursuant to PSU agreements under the Equity Plan (the &#8220;<span style="text-decoration: underline">PSU Award Agreements</span>&#8221;) and are subject to the
terms of the Company&#8217;s Policy Regarding Recoupment or Reduction of Incentive Compensation for Compliance Violations (clawback
policy), as in effect from time to time. A form of the PSU Award Agreement will be filed with the U.S. Securities and Exchange
Commission as an exhibit to the Annual Report on Form 10-K to be filed by the Company for the year ended December 31, 2020, and
such form qualifies the foregoing description of the PSUs by reference.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><b>&#160;</b></td>
    <td style="width: 50%"><b>REGENERON PHARMACEUTICALS, INC.&#160; &#160;</b></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">/s/ Joseph J. LaRosa</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Joseph J. LaRosa</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Executive Vice President, General Counsel and Secretary</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: January 5, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
